Precision Assessment of Platelet Rich Plasma for Joint Preservation
Trial ID or NCT#
Status
Purpose
Knee Osteoarthritis (OA) is a leading cause of premature disability in Veterans who develop knee OA at higher rates and younger ages than the population in general. For those with symptomatic early knee OA, who are years to decades away from meeting clinical indications for knee replacement surgery, knee injections have been a key treatment option. In recent years, platelet rich plasma (PRP) injections have gained increasing attention for improving pain and function in patients with knee OA. Basic science studies also suggest that PRP may also potentially stimulate repair responses to articular cartilage. However, the mechanisms of action of PRP in the treatment of knee OA are unknown. Because autologous blood is used, the PRP composition differs between patients. It is also unknown whether these differences in PRP composition affect clinical outcomes. This study will address these gaps and provide critical new and objective information on PRP treatment effects in Veterans and additional women with early knee OA important to improving clinical use of this new treatment.
Official Title
Precision Assessment of Platelet Rich Plasma for Joint Preservation
Eligibility Criteria
- - symptomatic early knee OA - full weight-bearing status - have elected to receive PRP treatment - Male veterans - Female veterans
- - inflammatory arthritis, gout or recurrent pseudogout - symptomatic OA of other lower extremity joints - BMI >35 kg/m2 - use of walking, orthopedic, or prosthetic assistive device - severe systemic disease defined as American Society of Anesthesiologists (ASA) 3 or above56 - inability to have MRI - pregnant or intending to become pregnant during the study - predominantly patellofemoral disease
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Gordhan B Mahtani, MSc
650-493-5000 Ext. 64431
View on ClinicalTrials.gov